Digest Network Come funziona
Network
/
Società
Cr
Non verificato

Crossbow Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaOncologiaSalute

4 comunicati stampa

Guarda tutti i comunicati
09/09/2026
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Crossbow Therapeutics Doses First Patient in Phase 1 Trial of CBX-663 for Treatment of Multiple Hematologic and Solid Malignancies
Fonte
Crossbow Therapeutics, Inc.
Emittente
Business Wire
1.00
0
18/03/2026
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
Crossbow Therapeutics Raises $77 Million in Series B Financing to Advance Development of TCR-mimetic Antibody Therapies to Treat Cancer
Fonte
Crossbow Therapeutics, Inc.
Emittente
Business Wire
1.00
0
16/09/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Industria
Crossbow Therapeutics Doses First Patient in Phase 1 Trial of CBX-250 for Myeloid Malignancies
Fonte
Crossbow Therapeutics, Inc.
Emittente
Business Wire
1.00
0
23/07/2025
Oncologia
Salute
Biologia
Medicina - Varie
Farmaceutica
Biotecnologia
Industria
Crossbow Therapeutics Nominates its Second Development Candidate, CBX-663, a Broadly Acting Therapeutic for a Wide Range of Solid and Hematologic Malignancies
Fonte
Crossbow Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0